On July 26, 2022 Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, reported that it has signed a new Licence and Supply Agreement ("LSA") with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies (Press release, Oxford BioMedica, JUL 26, 2022, View Source [SID1234616956]). The LSA grants the new partner a non-exclusive licence to utilise Oxford Biomedica’s LentiVector platform for its application in their lead CAR-T programme, and puts in place a three-year Clinical Supply Agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the LSA, Oxford Biomedica will receive an undisclosed upfront payment, as well as additional payments related to the development and manufacturing of lentiviral vectors for use in clinical trials. The Company will also receive certain development and regulatory milestone payments and an undisclosed royalty on the net sales of products sold that utilise the Company’s LentiVector platform.

Stuart Paynter, Chief Financial Officer of Oxford Biomedica, commented: "This new partnership further demonstrates the strength of our LentiVector platform. This is another example of our important role in supporting the development of potentially life-saving CAR-T therapies and has been made possible by the fact we’ve been able to offer strategically re-acquired targets to our customers. As a leading viral vector specialist, we look forward to continuing to build upon our position as a partner of choice in cell and gene therapy."